We recently released a list Buy 10 Worst Blue Chip Stocks. In this article, we will take a look at Merck & Co., Inc. (NYSE:MRK) represents the position of other worst blue chip stocks.
According to Niamh Brodie-Machura, co-chief investment officer of Fidelity International, the effect of tariffs is expected to shift lower when trading, supply chain adaptation, and some adjustments to the consumption patterns of witnesses for lower tariffs have been made, with witness witness demand relatively increasing. However, there is still a period of volatility and investors who plan to increase risk should be careful. Amid uncertainty, the environment is an opportunity to better position the portfolio as resilience.
Contrary to expectations, Blackrock emphasized in its April 23 release that international stocks outperformed U.S. stocks in 2025, with U.S. stocks down 11%. U.S. growth stocks fell 10%, while U.S. value stocks rose 2%. As value stocks continue to favor growth stocks, this transition indicates that there are significant market rotations throughout the geographic and style markets. Asset managers say that in the U.S. market, value stocks, mainly perform well in defense departments such as health care.
BlackRock also added that narrowing of the earnings gap and attractive features of the industry, such as innovation and growth in the aging population, have been intensifying performance. It is worth noting that active management strategies are beneficial when navigating volatile markets.
Also read: 7 Best Stocks to Buy Long-Term and 8 Cheap Jim Cramer Stock Investing.
BlackRock believes that large U.S. stocks are the only major U.S. index with a major U.S. return to YTD as of March 31. In value stocks, its investors are finding opportunities in the defensive sector. In the current rapidly developing political environment, mainly new trade policies, value stocks can have additional headwinds. This stems from their ability to earn more income from the United States.
The Trust, a private wealth management company, said that if elsewhere, if the tariff discussion lasts more than expected, or the average tariff rate is different from the current expectations, it is important to make portfolio changes. It is worth noting that capital expenditures on AI are expected to remain strong, and AI may promote long-term productivity. The company also believes that changes will be made to the bank's capital ratio rules, allowing it to enhance loans and/or increase stock buybacks. Both measures can increase income.
To list the 10 worst blue chip stock inventory to buy, we scanned the shares of SPDR® S&P500® ETFTrust and selected the YTD declined stock. After getting the list of expanded inventory, we selected stocks that are popular in hedge funds. Ultimately, as of the fourth quarter of 2024, these stocks were ranked in the rising order of their hedge fund holdings.
Why are we interested in stocks that hedge funds to accumulate? The reason is simple: Our research shows that we can beat the market by mimicking the top stocks of the best hedge funds. Our strategy for quarterly newsletters selects 14 small and large stocks every quarter, returning 373.4% since May 2014, beating its benchmark by 218 percentage points (See more details here).
Close-up of a man's hand holding a bottle of medicine.
Number of hedge fund holders: 91
% of YTD decline: about 23.3%
Merck & Co., Inc. (NYSE:MRK) is a leading global healthcare company. Bank of America Securities analyst Tim Anderson reiterated his “buy” rating of the company’s stock, priced at $99.00. Analysts’ ratings are backed by factors that demonstrate company growth potential and underestimate. Despite the small impact of tariffs and foreign exchange in Q1 Q1, analysts believe overall financial performance is strong. In addition, Anderson believes that Merck (NYSE:MRK) shares are still undervalued given the growth outlook and strong pipeline. The company has made greater contributions from new commercialized drugs and vaccines and continues to move forward, and the company has made healthy progress.
Keytruda's sales grew 6% in Q1 (excluding the impact of Forex). In earlier signs, global absorption is higher, including triple-negative breast cancer, renal cell carcinoma and non-small cell lung cancer, as well as continued strong global requirements, including growth in global demand, including growth in global content, including growth in global content, including growth in global content, including growth in global content, including growth in global content, including growth in global content and the company's growth in global content, including growth in global content and the company's growth in global results, including growth in global results and the company's growth in global results, including growth in global results and the company's growth in global results, including growth in global results and the company's growth in global results, including growth in global results and the company's growth in global results, including growth in global results and the company's growth in global results, including growth in global results and the company's growth in global results, including growth in global results and the company's growth in global results, including growth in global results and the company's growth in global results, including growth in global results and the company's growth in global results and the company's growth in global results and the company's growth in global results and the company's growth in global results and the company's growth in global results and the company's growth in global results and the company's growth in global results include growth in global results and the company's growth in global results and the company's growth in global results include growth in global results and the company's growth in global results and the company's growth in global results include growth in global results and the company's growth in global results and the company's growth in global results include growth in global results and the company's growth in global results and the company's growth in global results include growth in global results and the company's growth in global results and the company's growth in global results include growth in global results and the company's growth in global results include growth in global results and the company's growth in global results and the company's growth in global results include growth in global results and the company's growth in global results include growth in global results and the company's growth in global results include growth in global results and the company's growth in global results include growth in global results and the company's growth in global results include growth in global results (MSI-H) cancer, partially relieved by the timing of purchase in the United States. Overall, Merck & Co.
Investment management company Greenskeeper Asset Management released its third-quarter 2024 investor letter. here It's what the fund said:
“Merck (NYSE:MRK) This quarter was our second-largest critic, down -8.3%. MRK's leading HPV vaccine, Gardasil 9, faces international challenges due to stock accumulation at its Chinese distributors, which is expected to reduce shipments for the rest of 2024. Despite the short-term impact, the long-term prospects of Gardasil 9 remain promising. Meanwhile, the company's $27 billion Keytruda Cancer Juggernaut continues to grow with healthy editing, providing growth for revenue growth. ”
Overall, MRK Ranked third On our list of the worst blue chip stocks to buy. Although we acknowledge the potential of MRK is an investment, our belief is that some undervalued AI stocks have greater hope and can provide higher returns in a shorter time frame. AI stocks have risen since the beginning of 2025, while popular AI stocks have lost about 25%. If you are looking for an undervalued AI stock that is more promising than MRK but has traded for less than 5 times the price of its earnings, check out our report Cheapest AI stocks.
Read the next article: Buy 20 Best AI Stocks Now and According to the billionaire, there are now 30 best stocks.
Disclosure: None. This article was originally published in Inside monkey.